Ligand Pharmaceuticals Incorporated Forecast, price target & analysts
Ligand Pharmaceuticals Incorporated Target price 2025 - Analyst rating & recommendation
Ligand Pharmaceuticals Incorporated Classifications & Recommendation:
Ligand Pharmaceuticals Incorporated Price Target
| Target Price | $144.84 |
| Price | $113.76 |
| Potential |
27.32%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Ligand Pharmaceuticals Incorporated 2026 .
The average Ligand Pharmaceuticals Incorporated target price is $144.84.
This is
27.32%
register free of charge
$164.85
44.91%
register free of charge
$136.35
19.86%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Ligand Pharmaceuticals Incorporated to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ligand Pharmaceuticals Incorporated stock has an average upside potential 2026 of
27.32%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 167.13 | 197.90 |
| 27.28% | 18.41% | |
| EBITDA Margin | 33.54% | 39.39% |
| 0.61% | 17.43% | |
| Net Margin | -2.41% | 59.72% |
| 106.09% | 2,576.68% |
10 Analysts have issued a sales forecast Ligand Pharmaceuticals Incorporated 2025 . The average Ligand Pharmaceuticals Incorporated sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Ligand Pharmaceuticals Incorporated EBITDA forecast 2025. The average Ligand Pharmaceuticals Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Ligand Pharmaceuticals Incorporated Analysts have issued a net profit forecast 2025. The average Ligand Pharmaceuticals Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.22 | 6.22 |
| 107.64% | 2,927.27% | |
| P/E | 18.42 | |
| EV/Sales | 10.12 |
10 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast for earnings per share. The average Ligand Pharmaceuticals Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Ligand Pharmaceuticals Incorporated...
Current Ligand Pharmaceuticals Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
| Benchmark |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Apr 10 2025 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Dec 23 2024 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
